Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of BG00012 (dimethyl fumarate) in relapsing-remitting multiple sclerosis in Asia-Pacific and other regions
2013-004533-32Phase 3Completed
- Sponsor
- Biogen
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing BG00012 (dimethyl fumarate) with Placebo (2 arms). Primary endpoint: Total number of new Gd-enhancing lesions. Started Jan 2014; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2013-004533-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004533-32.